Blog
The J.M. Smucker Company’s Dividend: Too Sweet to Ignore?
Key Points
- Interested in The J. M. Smucker Company? Here are five stocks we like better.
- J.M. Smucker is undergoing a business transformation supported by activist investor Elliott Management
From Crypto to AI: Insiders Are Trading These 3 Stocks
Key Points
- Interested in Robinhood Markets, Inc.? Here are five stocks we like better.
- As crypto comes under pressure, insiders are buying a key name strongly associated with digital assets.
- One
The Case for Intel Over Pure-Play Quantum Firms
Key Points
- Interested in Intel Corporation? Here are five stocks we like better.
- Intel's 430% rally in the last year has given the company new momentum, even as investors may be overlooking its
Amgen Eyes 2026 ‘Springboard’ as Growth Drugs Offset Patent Pressure
Key Points
- Interested in Amgen Inc.? Here are five stocks we like better.
- Amgen said its strong first-quarter results support the idea that 2026 could be a “springboard year”, with revenue up
United Natural Foods Q3 Earnings Call Highlights
Key Points
- Interested in United Natural Foods, Inc.? Here are five stocks we like better.
- UNFI posted better profitability and cash flow in Q3 even as sales fell 4.2% to about $7.7 billion
Titan Machinery Q1 Earnings Call Highlights
Key Points
- Interested in Titan Machinery Inc.? Here are five stocks we like better.
- Titan Machinery’s first quarter came in slightly ahead of expectations, with revenue of $522.4 million down
SailPoint Q1 Earnings Call Highlights
Key Points
- Interested in SailPoint, Inc.? Here are five stocks we like better.
- SailPoint posted a strong Q1 with annual recurring revenue of $1.163 billion, up 26% year over year, and revenue
Lands' End Q1 Earnings Call Highlights
Key Points
- Interested in Lands' End, Inc.? Here are five stocks we like better.
- Q1 revenue fell 9% to $239 million as a distribution-center systems rollout delayed shipments, but management
Molten Ventures H2 Earnings Call Highlights
Key Points
- Interested in Molten Ventures Plc? Here are five stocks we like better.
- NAV and portfolio value rose strongly, with gross portfolio fair value up 13% and net asset value per share
EHang Q1 Earnings Call Highlights
Key Points
- Interested in EHang Holdings Limited Unsponsored ADR? Here are five stocks we like better.
- EHang said first-quarter revenue was roughly flat year over year at RMB 25.7 million, but
Apple's Siri AI Was Finally Announced, So Why Is the Stock Tanking?
Key Points
- Interested in Apple Inc.? Here are five stocks we like better.
- Apple briefly notched a record high of $317 on June 8 after the Siri AI announcement at WWDC, before reversing sharply.
Has Temu-Owner PDD's Story Changed After Double Miss?
Key Points
- Interested in PDD Holdings Inc. Sponsored ADR? Here are five stocks we like better.
- PDD is a huge player in Chinese e-commerce while also having a large non-Chinese presence through
Tanker Dividends Are Surging, But Income Investors Need to Watch the Cycle
Key Points
- Interested in Frontline PLC? Here are five stocks we like better.
- Frontline, Nordic American Tankers, and Euroseas all raised dividends recently, with Frontline boosting its payout by
These 3 Stocks Lowered Their Share Counts Drastically in Q1
Key Points
- Interested in Pinterest, Inc.? Here are five stocks we like better.
- Buyback authorizations are one thing, but companies actually executing on this potential spending is how
TH International Q1 Earnings Call Highlights
Key Points
- Interested in TH International Limited? Here are five stocks we like better.
- TH International reported weaker Q1 2026 results, with revenue down 14.6% year over year and same-store
J. M. Smucker Q4 Earnings Call Highlights
Key Points
- Interested in The J. M. Smucker Company? Here are five stocks we like better.
- J. M. Smucker posted solid fourth-quarter results, with net sales up 6% and adjusted EPS rising 20% to
Annexon Eyes ‘Win Season’ With Q4 Vision Trial Data, GBS Filings Ahead
Key Points
- Interested in Annexon, Inc.? Here are five stocks we like better.
- Annexon’s biggest near-term catalyst is fourth-quarter Phase III data for vonaprument in geographic atrophy, where
Cybersecurity Earnings: 1 AI Standout and 2 Stocks Under Pressure
Key Points
- Interested in Okta, Inc.? Here are five stocks we like better.
- Okta surged nearly 48% over two days after beating estimates and citing strong demand for its AI agent identity
AirJoule Technologies: A Cool Shot at a Multibagger
Key Points
- Interested in AirJoule Technologies Corporation? Here are five stocks we like better.
- AirJoule is on track to commercialize its technology, which is reflected in the stock's price.
Walmart's No. 2 Ranking Hides a Digital Transformation Story
Key Points
- Interested in Walmart Inc.? Here are five stocks we like better.
- Walmart Connect is becoming a major profit driver, with advertising revenue growing far faster than the company's core
Campbell's Soup Stock: Deep Value and a 7% Dividend Yield
Key Points
- Interested in The Campbell's Company? Here are five stocks we like better.
- Campbell's Soup Company is in position to rebound and enter price recovery as it transitions back to growth.
Caribou Biosciences Says CRISPR CAR-T Is Pivotal-Ready, CB-011 Data Nears
Key Points
- Interested in Caribou Biosciences, Inc.? Here are five stocks we like better.
- Vispa-cel, Caribou’s off-the-shelf CRISPR CAR-T for lymphoma, is now “pivotal-ready,” and the company
Oxford Instruments H2 Earnings Call Highlights
Key Points
- Interested in Oxford Instruments plc? Here are five stocks we like better.
- Oxford Instruments said full-year results came in slightly ahead of expectations, with second-half order
Corbus Pharmaceuticals Teases Cancer, Obesity Data as Key Clinical Readouts Near
Key Points
- Interested in Corbus Pharmaceuticals Holdings, Inc.? Here are five stocks we like better.
- Corbus Pharmaceuticals highlighted encouraging Phase 1 data for CRB-701 in cervical and
Hemab Therapeutics Details Post-IPO Pipeline Push, Sutacimig Phase III Plans
Key Points
- Interested in Hemab Therapeutics Holdings, Inc.? Here are five stocks we like better.
- Hemab Therapeutics said its lead drug sutacimig is on track to enter a pivotal Phase III trial